Journal of clinical oncology : official journal of the American Society of Clinical OncologyHumansDaunorubicinChildFemaleAdolescent
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.
Hanna Gottschalk, Anja Möricke, Valentino Conter, Martin Schrappe, Jan Starý, Gunnar Cario, Michael Dworzak, Andishe Attarbaschi, Draga Barbaric, Franco Locatelli, Nicole Bodmer, Sarah Elitzur, Daniela Silvestri, Luciano Dalla-Pozza, Anke Katharina Bergmann
Published: 202510.1200/JCO-25-01357
Abstract
PURPOSE: Modern ALL therapy aims to reduce toxicity, while maintaining and improving the current high cure rates. Acute and late sequelae of anthracyclines are of major concern. The AIEOP-BFM ALL 2009 trial aimed to clarify the need for anthracycline…
Preview only. Read the full abstract at the source